These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34669417)

  • 1. Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.
    Liu S; Qiao W; Sun Q; Luo Y
    J Med Chem; 2021 Nov; 64(21):15534-15548. PubMed ID: 34669417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
    Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
    Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1.
    Lei Y; An Q; Shen XF; Sui M; Li C; Jia D; Luo Y; Sun Q
    J Med Chem; 2021 May; 64(10):6596-6607. PubMed ID: 33974430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomic basis of CRM1-cargo recognition, release and inhibition.
    Fung HY; Chook YM
    Semin Cancer Biol; 2014 Aug; 27():52-61. PubMed ID: 24631835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophile Determines Cellular Phenotypes among XPO1-Targeting Small Molecules.
    Chen YF; Shen Y; Yan DF; Ghazala M; Scemama de Gialluly MA; Srinivasan R; Farrar AN; Friedrich RM; Adams DJ
    J Med Chem; 2024 Jul; 67(14):12033-12054. PubMed ID: 39005064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
    Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
    PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
    Niu M; Chong Y; Han Y; Liu X
    Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
    von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
    Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
    Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
    Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
    Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
    Etchin J; Sun Q; Kentsis A; Farmer A; Zhang ZC; Sanda T; Mansour MR; Barcelo C; McCauley D; Kauffman M; Shacham S; Christie AL; Kung AL; Rodig SJ; Chook YM; Look AT
    Leukemia; 2013 Jan; 27(1):66-74. PubMed ID: 22847027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
    Abeykoon JP; Wu X; Nowakowski KE; Dasari S; Paludo J; Weroha SJ; Hu C; Hou X; Sarkaria JN; Mladek AC; Phillips JL; Feldman AL; Ravindran A; King RL; Boysen J; Stenson MJ; Carr RM; Manske MK; Molina JR; Kapoor P; Parikh SA; Kumar S; Robinson SI; Yu J; Boughey JC; Wang L; Goetz MP; Couch FJ; Patnaik MM; Witzig TE
    Blood; 2021 Jan; 137(4):513-523. PubMed ID: 33507295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
    Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
    Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
    Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
    Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
    Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
    Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
    Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
    J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
    Tai YT; Landesman Y; Acharya C; Calle Y; Zhong MY; Cea M; Tannenbaum D; Cagnetta A; Reagan M; Munshi AA; Senapedis W; Saint-Martin JR; Kashyap T; Shacham S; Kauffman M; Gu Y; Wu L; Ghobrial I; Zhan F; Kung AL; Schey SA; Richardson P; Munshi NC; Anderson KC
    Leukemia; 2014 Jan; 28(1):155-65. PubMed ID: 23588715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection.
    Lu C; Figueroa JA; Liu Z; Konala V; Aulakh A; Verma R; Cobos E; Chiriva-Internati M; Gao W
    Curr Cancer Drug Targets; 2015; 15(7):575-92. PubMed ID: 26324128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the nuclear transport machinery by rational drug design.
    Mao L; Yang Y
    Curr Pharm Des; 2013; 19(12):2318-25. PubMed ID: 23082981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.